Literature DB >> 26135229

In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles.

Marilena Hadjidemetriou, Zahraa Al-Ahmady, Mariarosa Mazza, Richard F Collins, Kenneth Dawson1, Kostas Kostarelos.   

Abstract

The adsorption of proteins and their layering onto nanoparticle surfaces has been called the "protein corona". This dynamic process of protein adsorption has been extensively studied following in vitro incubation of many different nanoparticles with plasma proteins. However, the formation of protein corona under dynamic, in vivo conditions remains largely unexplored. Extrapolation of in vitro formed protein coronas to predict the fate and possible toxicological burden from nanoparticles in vivo is of great interest. However, complete lack of such direct comparisons for clinically used nanoparticles makes the study of in vitro and in vivo formed protein coronas of great importance. Our aim was to study the in vivo protein corona formed onto intravenously injected, clinically used liposomes, based on the composition of the PEGylated liposomal formulation that constitutes the anticancer agent Doxil. The formation of in vivo protein corona was determined after the recovery of the liposomes from the blood circulation of CD-1 mice 10 min postinjection. In comparison, in vitro protein corona was formed by the incubation of liposomes in CD-1 mouse plasma. In vivo and in vitro formed protein coronas were compared in terms of morphology, composition and cellular internalization. The protein coronas on bare (non-PEGylated) and monoclonal antibody (IgG) targeted liposomes of the same lipid composition were also comparatively investigated. A network of linear fibrillary structures constituted the in vitro formed protein corona, whereas the in vivo corona had a different morphology but did not appear to coat the liposome surface entirely. Even though the total amount of protein attached on circulating liposomes correlated with that observed from in vitro incubations, the variety of molecular species in the in vivo corona were considerably wider. Both in vitro and in vivo formed protein coronas were found to significantly reduce receptor binding and cellular internalization of antibody-conjugated liposomes; however, the in vivo corona formation did not lead to complete ablation of their targeting capability.

Entities:  

Keywords:  Doxil; fibrillation; nanomedicine; nanoparticle; nanotoxicology; protein corona

Mesh:

Substances:

Year:  2015        PMID: 26135229     DOI: 10.1021/acsnano.5b03300

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  59 in total

Review 1.  Protein corona: Opportunities and challenges.

Authors:  Saeid Zanganeh; Ryan Spitler; Mohsen Erfanzadeh; Alaaldin M Alkilany; Morteza Mahmoudi
Journal:  Int J Biochem Cell Biol       Date:  2016-01-16       Impact factor: 5.085

2.  Nanomedicine: Evolution of the nanoparticle corona.

Authors:  Marilena Hadjidemetriou; Kostas Kostarelos
Journal:  Nat Nanotechnol       Date:  2017-04-06       Impact factor: 39.213

3.  Tackling chondrocyte hypertrophy with multifunctional nanoparticles.

Authors:  M Bottini; A Magrini; B Fadeel; N Rosato
Journal:  Gene Ther       Date:  2016-04-14       Impact factor: 5.250

Review 4.  Target Site Delivery and Residence of Nanomedicines: Application of Quantitative Systems Pharmacology.

Authors:  Jessie L-S Au; Roberto A Abbiati; M Guillaume Wientjes; Ze Lu
Journal:  Pharmacol Rev       Date:  2019-04       Impact factor: 25.468

5.  A Comparative In Vivo Study of Albumin-Coated Paclitaxel Nanocrystals and Abraxane.

Authors:  Joonyoung Park; Ji Eun Park; Victoria E Hedrick; Karl V Wood; Connie Bonham; Wooin Lee; Yoon Yeo
Journal:  Small       Date:  2018-03-23       Impact factor: 13.281

Review 6.  Strategies for improving drug delivery: nanocarriers and microenvironmental priming.

Authors:  Ayesha Khalid; Stefano Persano; Haifa Shen; Yuliang Zhao; Elvin Blanco; Mauro Ferrari; Joy Wolfram
Journal:  Expert Opin Drug Deliv       Date:  2016-10-11       Impact factor: 6.648

Review 7.  The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery.

Authors:  Claudia Corbo; Roberto Molinaro; Alessandro Parodi; Naama E Toledano Furman; Francesco Salvatore; Ennio Tasciotti
Journal:  Nanomedicine (Lond)       Date:  2015-12-11       Impact factor: 5.307

8.  Materials design at the interface of nanoparticles and innate immunity.

Authors:  Gregory Lee Szeto; Erin B Lavik
Journal:  J Mater Chem B       Date:  2016-01-29       Impact factor: 6.331

9.  The biocorona: a challenge for the biomedical application of nanoparticles.

Authors:  Jonathan Shannahan
Journal:  Nanotechnol Rev       Date:  2017-01-20       Impact factor: 7.848

10.  Profiling the Serum Protein Corona of Fibrillar Human Islet Amyloid Polypeptide.

Authors:  Emily H Pilkington; Ove J R Gustafsson; Yanting Xing; Juan Hernandez-Fernaud; Cleidi Zampronio; Aleksandr Kakinen; Ava Faridi; Feng Ding; Paul Wilson; Pu Chun Ke; Thomas P Davis
Journal:  ACS Nano       Date:  2018-05-16       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.